Search Results
Burnett, A. K.: Treatment of acute myeloid leukemia: are we making progress? Hematology Am. Soc. Hematol. Educ. Program, 2012, 2012 (1), 1–6. Mrózek, K., Marcucci, G
458 Bennett, J. M., Catovsky, D., Daniel, M. T., et al.: Proposed revised criteria for the classification af acute myeloid leukaemia. Ann. Intern. Med., 1985, 103 , 636
2302 Mrozek, K., Marucci, G., Paschka, P. és mtsai: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we
leukemia. J Clin Oncol. 2012; 30: 4515–23. 14 Podoltsev NA, Stahl M, Zeidan AM, et al. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017; 31
. 2 Noone AM, Howlader N, Krapcho M, et al. SEER Stat Fact Sheets: Acute Myeloid Leukemia (AML) NIH [online] https://seer.cancer.gov/statfacts/html/amyl.html 3
acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
] 12 Pagano L, Pulsoni A, Vignetti M, et al. Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. Ann Oncol. 2005; 16: 228
–1842. 2 Willander K, Falk IJ, Chaireti R, et al. Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomark Res. 2014; 2: 18
), 254–269. 2 Smith, M. L., Cavenagh, J. D., Lister, T. A., et al.: Mutation of CEBPA in familial acute myeloid leukemia. N. Engl. J. Med., 2004, 351 (23), 2403
myeloid leukemia. Blood 2019; 133: 7–17. 15 Aldoss I, Zhang J, Pillai R, et al.: Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. Br J